Question
Discuss the issues concerning HIV vaccine.
Answer :
Word Count : 306
_____ ___ __________ __________ ______ _________.
______ ________ _______ ___ __________ _____.
___ _______ _____ ____ __________.
_______ ___ _____ __________ ___ _______ ____ ______ ____ _________ ______ __________.
______ ________ ____ _________ _________ _______ _________ ________ ___ ________ ________.
_________ ____ ___ ________ ____.
_______ ______ ____ _________ ____ ________ __________.
_______ _____ _______ _________ _____ ____ ___ _______.
________ __________ __________ ___ _______ ___.
______ _______ ____ _________ ________ _____ ________ ______.
______ _____ ____ ___ __________ ______ __________ ____ ________ _________.
____ _______ ___ _______ ______ ____ _________ _____ ________ _________.
__________ __________ __________ ________ ____ _________ ___ _____ ____ ________ _________ ___.
_____ _____ _________ ______ _______ ____ ____ _________ ____.
_______ _______ ________ ________ ______ _____ __________ ________ ___.
__________ _________ _____ ________ _____ __________ ____ __________ ______ __________ _________ _______.
________ _____ _______ ___ ___ ____ ____ ___ _____.
_______ ________ _________ ______ _________ ________ _________ __________ ___ ________ ______.
_________ ________ ___ ________ ________ ______ ______ _____ _______.
_______ ________ _________ ____ __________ _____ _____ _____.
___.
Skip in 10
The development of an HIV vaccine faces multiple scientific, social, and ethical challenges. One of the primary scientific obstacles is the high genetic variability of the HIV virus. HIV mutates rapidly, producing numerous strains, which makes it difficult to create a single vaccine that can provide broad and long-lasting protection. Unlike other viruses, HIV targets the immune system itself, particularly the CD4+ T-cells, complicating the ability of a vaccine to generate effective immunity. Additionally, the virus integrates into the host genome, establishing reservoirs that evade both natural immune responses and potential vaccine-induced protection. Another challenge concerns the identification of appropriate immune responses that a vaccine should induce. Researchers are still determining whether neutralizing antibodies, cytotoxic T lymphocytes, or a combination of immune
________ ________ ______ ____ __________ ______ ____ __________ _________ ______._____ ___ __________ __________ ______ _________.
______ ________ _______ ___ __________ _____.
___ _______ _____ ____ __________.
_______ ___ _____ __________ ___ _______ ____ ______ ____ _________ ______ __________.
______ ________ ____ _________ _________ _______ _________ ________ ___ ________ ________.
_________ ____ ___ ________ ____.
_______ ______ ____ _________ ____ ________ __________.
_______ _____ _______ _________ _____ ____ ___ _______.
________ __________ __________ ___ _______ ___.
______ _______ ____ _________ ________ _____ ________ ______.
______ _____ ____ ___ __________ ______ __________ ____ ________ _________.
____ _______ ___ _______ ______ ____ _________ _____ ________ _________.
__________ __________ __________ ________ ____ _________ ___ _____ ____ ________ _________ ___.
_____ _____ _________ ______ _______ ____ ____ _________ ____.
_______ _______ ________ ________ ______ _____ __________ ________ ___.
__________ _________ _____ ________ _____ __________ ____ __________ ______ __________ _________ _______.
________ _____ _______ ___ ___ ____ ____ ___ _____.
_______ ________ _________ ______ _________ ________ _________ __________ ___ ________ ______.
_________ ________ ___ ________ ________ ______ ______ _____ _______.
_______ ________ _________ ____ __________ _____ _____ _____.
___.
IGNOU ACADEMY
Your IGNOU journey, made easier.
- Solved Assignments
- Study Notes
- Guess Papers
- Question Papers
Continue Reading — It's Free
Sign in with Google to unlock more of this answer.
✓ Free access
✓ Unlock up to 60% of the answer
✓ No payment required
✓ Unlock up to 60% of the answer
✓ No payment required
Quick Google sign-in. No separate registration form.